
Q&A: Sequencing treatment options for BCG-unresponsive NMIBC
Key Takeaways
- The proliferation of bladder-sparing therapies has increased decision complexity because comparative efficacy and durability data across agents remain limited.
- Patient-centered selection should incorporate urinary symptom burden, functional capacity to complete repeated intravesical visits, caregiver logistics, and treatment-associated financial toxicity.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
In this Q&A, Sam S. Chang, MD, MBA, discusses the evolving treatment landscape for patients with BCG-unresponsive non–muscle invasive
Chang is the Chief Surgical Officer at Vanderbilt-Ingram Cancer Center and professor of urology at Vanderbilt University School of Medicine in Nashville, Tennessee.
Urology Times: How would you characterize the current treatment landscape for patients with BCG-unresponsive NMIBC?
Chang: This is a landscape that is continuing to evolve with ongoing clinical trials and new [treatment] options that can actually be discussed with patients. So it is promising and exciting, but has become a bit more complicated because we have these choices, and there's no direct comparison between different types of agents.
Urology Times: As you mentioned, there are several bladder-sparing options now available. What considerations help determine which treatment to use first after BCG failure?
Chang: Choosing the right treatment has become more complicated because we went from no choices to multiple options. You need to consider a patient's ability to handle treatment. In other words, [you need to consider] their baseline urinary symptoms [or] their dependence upon others to make it to a number of clinic visits vs a limited number of visits. When we discuss treatments with patients, patients worry about efficacy, the duration of response, but they have to take into account how difficult is this for me to get? And by difficult I mean what kind of burden is it on me, and on my support system?
Cost is important as well. These medications do carry a significant cost. As patients consider that, you need to also consider clinical trials. Should we think about something that's not FDA approved? That would include combination chemotherapy agents. So there’s a lot of things to consider. Each one of these should be personalized. One cannot say one is better than any other, but one may be better for that individual patient depending on his or her situation.
Urology Times: What factors most strongly influence your decision to pursue another bladder-sparing treatment vs recommending radical cystectomy?
Chang: That jumping off point between trying to do a bladder-preserving therapy vs radical cystectomy has now also become more nuanced and more difficult, which is a good thing. You worry about the specific disease characteristics. Certain disease characteristics make me more concerned—for example, a T1 bladder cancer as opposed to a small Ta bladder cancer. If the patient has a very poorly functioning bladder, it's difficult to have him or her undergo more intravesical treatments of any kind.
It's also important to consider the results of the CISTO trial. The CISTO trial showed, although in a non-randomized fashion, that for patients' quality of life and physical wellbeing, radical cystectomy for many patients was the right choice for them. All of those things come into play before making that decision, and it goes back to shared decision-making and personalizing the decision that is important. I don't think we're in this realm now of “this is the best choice” and “this is the second, third, fourth”. We don't have that pecking order, but we do need to discuss all these options and personalize that decision.
Urology Times: Looking ahead, how do you see the treatment landscape for BCG-unresponsive NMIBC evolving over the next few years?
Chang: There are going to be more choices that become available and I hope we get actual evidence that talk about sequencing—about what medication or intervention may be better first-line, second-line, or in combination. These all work in a bit of a different mechanism of action. [This is] somewhat different from prostate cancer where the androgen pathway is really important. In non–muscle invasive bladder cancer that's BCG unresponsive, we have chemotherapy agents, immunotherapy agents, agents combined with BCG, off the shelf [therapies, etc.] We have all these different types of things being studied and evaluated, and I think we're going to need future study to compare and determine what may be better in a certain situation vs others. That data will become increasingly important because there are going to be more options out there.
Related to this article







